Optimizing the management of HER2-negative metastatic breast cancer with capecitabine (Xeloda)

被引：7
|
作者：
Leonard, R
Miles, D
Reichardt, P
Twelves, C
机构：
[1] S Wales Canc Inst, Swansea, W Glam, Wales
[2] Guys & St Thomas Hosp, London SE1 9RT, England
[3] HELIOS Klinikum, Dept Hematol Oncol & Tumorimmunol, Berlin, Germany
[4] Univ Leeds, Leeds LS2 9JT, W Yorkshire, England
[5] Bradford Royal Infirm, Bradford BD9 6RJ, W Yorkshire, England
来源：
SEMINARS IN ONCOLOGY | 2004年 / 31卷 / 05期
关键词：
D O I：
10.1053/j.seminoncol.2004.07.018
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：21 / 28
页数：8
相关论文
共 50 条
  • [1] Adjuvant capecitabine for HER2-negative breast cancer
    Burki, Talha Khan
    LANCET ONCOLOGY, 2017, 18 (07): : E375 - E375
  • [2] A retrospective comparison of eribulin and capecitabine in patients with HER2-negative metastatic breast cancer
    Tsushita, N.
    Shimoi, T.
    Okuma, H. S.
    Kawachi, A.
    Kitano, A.
    Nishikawa, T.
    Shimomura, A.
    Noguchi, E.
    Kodaira, M.
    Yunokawa, M.
    Yonemori, K.
    Shimizu, C.
    Fujiwara, Y.
    Tamura, K.
    ANNALS OF ONCOLOGY, 2016, 27
  • [3] Current approaches to the management of Her2-negative metastatic breast cancer
    Gogineni, Keerthi
    DeMichele, Angela
    BREAST CANCER RESEARCH, 2012, 14 (02)
  • [4] Current approaches to the management of Her2-negative metastatic breast cancer
    Keerthi Gogineni
    Angela DeMichele
    Breast Cancer Research, 14
  • [5] Capecitabine in Combination with Docetaxel in First Line in HER2-Negative Metastatic Breast Cancer: an Observational Study
    Koszo, Renata
    Santha, Dra
    Budi, Laszl
    Erfan, Jzsef
    Gyorfy, Karoly
    Horvath, Zsolt
    Kocsis, Judit
    Landherr, Laszlo
    Hitre, Erika
    Mahr, Karoly
    Pajkos, Gabor
    Papai, Zsuzsanna
    Kahan, Zsuzsanna
    PATHOLOGY & ONCOLOGY RESEARCH, 2017, 23 (03) : 505 - 511
  • [6] Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer
    Babacan, Taner
    Efe, Orhan
    Hasirci, Ahmet S.
    Demirci, Fatih
    Buyukhatipoglu, Hakan
    Balakan, Ozan
    Sarici, Furkan
    Kertmen, Neyran
    Esin, Ece
    Akin, Serkan
    Ates, Ozturk
    Aksoy, Sercan
    Sever, Ali R.
    Altundag, Kadri
    TUMORI JOURNAL, 2015, 101 (04): : 418 - 423
  • [7] Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide in patients with HER2-negative metastatic breast cancer
    Ohtani, S.
    Fujihara, M.
    ANNALS OF ONCOLOGY, 2015, 26 : 30 - 30
  • [8] A Phase I Trial of Alpelisib Combined With Capecitabine in Patients With HER2-Negative Metastatic Breast Cancer
    File, Danielle M.
    Abdou, Yara
    Force, Jeremy
    Moore, Dominic T.
    Anders, Carey K.
    Reeder-Hayes, Katherine
    Carey, Lisa A.
    Muss, Hyman B.
    Perou, Charles M.
    Marcom, P. Kelly
    Dees, E. Claire
    CLINICAL BREAST CANCER, 2024, 24 (08) : 683 - 690
  • [9] Advances in chemotherapy for HER2-negative metastatic breast cancer
    Mukai, Hirofumi
    Ito, Mayuko
    CHINESE CLINICAL ONCOLOGY, 2018, 7 (03)
  • [10] Capecitabine and Vinorelbine as an All-Oral Chemotherapy in HER2-Negative Locally Advanced and Metastatic Breast Cancer
    Gampenrieder, Simon P.
    Bartsch, Rupert
    Matzneller, Peter
    Pluschnig, Ursula
    Dubsky, Peter
    Gnant, Michael X.
    Zielinski, Christoph C.
    Steger, Guenther G.
    BREAST CARE, 2010, 5 (03) : 158 - 162
12345